Gast ::
| Hauptseite > Publikationsdatenbank > Indication of retrograde tau spreading along Braak stages and functional connectivity pathways > print |
| Hauptseite > Publikationsdatenbank > Indication of retrograde tau spreading along Braak stages and functional connectivity pathways > print |
| 001 | 904374 | ||
| 005 | 20230123101851.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-020-05183-1 |2 doi |
| 024 | 7 | _ | |a 0340-6997 |2 ISSN |
| 024 | 7 | _ | |a 1432-105X |2 ISSN |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 024 | 7 | _ | |a 2128/32256 |2 Handle |
| 024 | 7 | _ | |a 33462630 |2 pmid |
| 024 | 7 | _ | |a WOS:000608658400001 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-05944 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Seemiller, Joseph |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Indication of retrograde tau spreading along Braak stages and functional connectivity pathways |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2021 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667375291_21228 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Purpose: Tau pathology progression in Alzheimer's disease (AD) is explained through the network degeneration hypothesis and the neuropathological Braak stages; however, the compatibility of these models remains unclear.Methods: We utilized [18F]AV-1451 tau-PET scans of 39 subjects with AD and 39 sex-matched amyloid-negative healthy controls (HC) in the ADNI (Alzheimer's Disease Neuroimaging Initiative) dataset. The peak cluster of tau-tracer uptake was identified in each Braak stage of neuropathological tau deposition and used to create a seed-based functional connectivity network (FCN) using 198 HC subjects, to identify healthy networks unaffected by neurodegeneration.Results: Voxel-wise tau deposition was both significantly higher inside relative to outside FCNs and correlated significantly and positively with levels of healthy functional connectivity. Within many isolated Braak stages and regions, the correlation between tau and intrinsic functional connectivity was significantly stronger than it was across the whole brain. In this way, each peak cluster of tau was related to multiple Braak stages traditionally associated with both earlier and later stages of disease.Conclusion: We show specificity of healthy FCN topography for AD-pathological tau as well as positive voxel-by-voxel correlations between pathological tau and healthy functional connectivity. We propose a model of "up- and downstream" functional tau progression, suggesting that tau pathology evolves along functional connectivity networks not only "downstream" (i.e., along the expected sequence of the established Braak stages) but also in part "upstream" or "retrograde" (i.e., against the expected sequence of the established Braak stages), with pathology in earlier Braak stages intensified by its functional relationship to later disease stages.Keywords: Alzheimer’s disease; Braak stage; Functional connectivity; Network degeneration hypothesis; PET; Tau. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 536 | _ | _ | |a 5254 - Neuroscientific Data Analytics and AI (POF4-525) |0 G:(DE-HGF)POF4-5254 |c POF4-525 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Bischof, Gerard Nisal |0 P:(DE-Juel1)166265 |b 1 |
| 700 | 1 | _ | |a Hönig, Merle |0 P:(DE-Juel1)178642 |b 2 |
| 700 | 1 | _ | |a Tahmasian, Masoud |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a van Eimeren, Thilo |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 5 |
| 700 | 1 | _ | |a Initiative, the Alzheimer’s Disease Neuroimaging |0 P:(DE-HGF)0 |b 6 |
| 773 | _ | _ | |a 10.1007/s00259-020-05183-1 |g Vol. 48, no. 7, p. 2272 - 2282 |0 PERI:(DE-600)2098375-X |n 7 |p 2272 - 2282 |t European journal of nuclear medicine and molecular imaging |v 48 |y 2021 |x 0340-6997 |
| 856 | 4 | _ | |y OpenAccess |z StatID:(DE-HGF)0510 |u https://juser.fz-juelich.de/record/904374/files/Indication%20of%20retrograde%20tau%20spreading_Seemiller.docx |
| 856 | 4 | _ | |y Restricted |u https://juser.fz-juelich.de/record/904374/files/Seemiller2021_Article_IndicationOfRetrogradeTauSprea.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:904374 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Department of Neurology, Geisinger Medical Center, 100 N. Academy Ave, Danville, PA, 17822, USA. joe@josephseemiller.com |0 I:(DE-HGF)0 |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany |0 I:(DE-HGF)0 |b 1 |6 P:(DE-Juel1)166265 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)178642 |
| 910 | 1 | _ | |a Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany |0 I:(DE-HGF)0 |b 2 |6 P:(DE-Juel1)178642 |
| 910 | 1 | _ | |a Institute of Medical Science and Technology, Shahid Beheshti University, Tehran, Iran |0 I:(DE-HGF)0 |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany |0 I:(DE-HGF)0 |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Germany |0 I:(DE-HGF)0 |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany |0 I:(DE-HGF)0 |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany |0 I:(DE-HGF)0 |b 5 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Germany |0 I:(DE-HGF)0 |b 5 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a the Alzheimer’s Disease Neuroimaging Initiative |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5254 |x 1 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-02-02 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-02 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-02-02 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-02 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-02-02 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-02 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|